Cargando…
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM). Supportive therapies have shown limited benefits, mostly related to diuretics for the relief from...
Autores principales: | Tomasoni, Daniela, Bonfioli, Giovanni Battista, Aimo, Alberto, Adamo, Marianna, Canepa, Marco, Inciardi, Riccardo M., Lombardi, Carlo Mario, Nardi, Matilde, Pagnesi, Matteo, Riccardi, Mauro, Vergaro, Giuseppe, Vizzardi, Enrico, Emdin, Michele, Metra, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242061/ https://www.ncbi.nlm.nih.gov/pubmed/37288260 http://dx.doi.org/10.3389/fcvm.2023.1154594 |
Ejemplares similares
-
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023) -
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis
por: Cersosimo, Angelica, et al.
Publicado: (2023) -
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis
por: Pagnesi, Matteo, et al.
Publicado: (2022) -
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
por: Riccardi, Mauro, et al.
Publicado: (2022) -
Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)